ABI-110 is under clinical development by Avirmax and currently in Phase II for Polypoidal Choroidal Vasculopathy. According to GlobalData, Phase II drugs for Polypoidal Choroidal Vasculopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ABI-110 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABI-110 overview
AVMX-110 is under development for the treatment of wet age-related macular degeneration (wAMD) and polypoidal choroidal vasculopathy (PCV). The drug candidate comprises a recombinant adeno-associated virus (AAV) vector encoding therapeutic gene. It is being developed based on the BAC-to-AAV technology platform. It is administered through intravitreal route.
It was also under development for choroidal neovascularization, diabetic macular retinopathy (DMR) and retinal vein occlusion.
Avirmax overview
Avirmax, Inc ( Avirmax) is a biotechnology services company which innovate, develop and manufacture adeno-associated virus mediated biotherapeutic. Avirmax is headquartered in the US.
For a complete picture of ABI-110’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
